Patent · US Active

TLR9-binding chimeric antigen receptors

US11286306B2 · kind B2 · utility

1Cited by

1References

17Claims

0Family size

Assignee

H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC. · US

Inventors

Daniel Abate-Daga · Tampa, US
Alan F. List · Tampa, US
Sheng Wei · Tampa, US

Key dates

Filing date	Dec 8, 2017
Grant date	Mar 29, 2022
Priority date	—
Expiry date	Jun 3, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/33
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill cancer cells that express TLR9 on their surface. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a TLR9-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.